Innovator. Advocate.Together with patients, on a mission to advance transformative treatments for people living with serious cardiometabolic diseases.
At Akcea, we’re on a mission to transform the treatment of unaddressed or under-addressed lipid-based cardiometabolic disorders with leading-edge, RNA-targeted medicines. Whether you’re a patient living with a serious lipid disorder, or a physician whose patient desperately needs a therapy, we know you’re counting on us, and it fuels our unwavering commitment to be a partner to the community through innovation.
Cardiometabolic Lipid Disorders
There is a significant need for new therapies targeting the protein and lipid risk factors associated with these serious, complex diseases
Volanesorsen – Our Lead Program for FCS and FPL
Phase 3 studies are underway to treat two rare, genetically defined lipid disorders that severely impact the lives of those affected
February 07, 2018
Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx
Learning about familial chylomicronemia syndrome (FCS)
FCS is a rare, genetic disease caused by an enzyme deficiency that leads to the buildup of chylomicrons and a high risk of life-threatening pancreatitisVisit FCSFocus.com